...
首页> 外文期刊>Infectious Diseases and Therapy >Paediatric Recurrent Ear, Nose and Throat Infections and Complications: Can We Do More?
【24h】

Paediatric Recurrent Ear, Nose and Throat Infections and Complications: Can We Do More?

机译:小儿复发耳,鼻子和喉咙感染和并发症:我们可以做更多吗?

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Recurrent respiratory tract infections (rRTIs), of which there are three main groups—otitis media, tonsillitis and sinusopathies—are very common in paediatric populations and are associated with significant morbidity and mortality due to complications. These infections substantially reduce quality of life for paediatric patients and their families and are a significant personal, medical and economic burden on the patients, the patients’ families and the healthcare system. Most rRTIs are of viral origin; however, indiscriminate use of antibiotics in their treatment has led to development of bacterial resistance. Effective management of rRTIs to reduce the burden of disease and to avoid overuse of antibiotics has become a great therapeutic challenge. New strategies for the management of paediatric rRTIs include focus on prevention using non-specific immunomodulators to boost the body’s natural defences against infection and to downregulate infection- and allergen-induced airway inflammation. The oral immunomodulator, OM-85, a bacterial lysate, acts on the innate and adaptive branches of the immune system, conferring protection against viral and bacterial infections, and controls inflammation, thereby reducing tissue damage. OM-85 has demonstrated good tolerability and clinical efficacy in reducing the number and duration of RTIs in children with recurrent airway infections. It has also been reported to reduce the use of concomitant medications, including antibiotics, time to cure and school absenteeism. OM-85 is efficacious and well tolerated when administered concomitantly with inactivated influenza vaccine (IIV) and has been shown to reduce wheezing attacks induced by RTI in young children. Clinical results show that the greater the risk of rRTIs, the greater the benefit with OM-85. OM-85 may be considered a promising tool to add to the limited armamentarium of the ear, nose and throat (ENT) physician dealing with rRTIs and their complications, such as recurrent wheeze and asthma inception.
机译:复发性呼吸道感染(RRTIS),其中存在三个主要群体 - 中耳炎,扁桃体炎和鼻病 - 在儿科群体中是非常常见的,并且由于并发症而与显着的发病率和死亡率有关。这些感染大大降低了儿科患者及其家庭的生活质量,对患者,患者家属和医疗保健系统具有重要的个人,医疗和经济负担。大多数RRTIS都是病毒来源;然而,在其治疗中滥用抗生素的使用导致了细菌抗性的发展。有效管理RRTIS以减轻疾病负担,避免过度使用抗生素已成为一个巨大的治疗挑战。儿科RRTIS管理的新策略包括使用非特异性免疫调节器的预防,促进身体的自然防御感染,并降低感染和过敏原诱导的气道炎症。口腔免疫调节剂,OM-85,一种细菌裂解物,作用于免疫系统的先天和适应分支,赋予病毒和细菌感染的保护,并控制炎症,从而降低组织损伤。 OM-85证明了在减少经常性气道感染的儿童的RTIS的数量和持续时间方面表现出良好的耐受性和临床疗效。还据报道,还减少了伴随药物的使用,包括抗生素,治疗和学校缺勤的时间。当伴随着灭活的流感疫苗(IIV)伴随时,OM-85是有效且耐受性,并且已被证明可以减少幼儿RTI诱导的喘息攻击。临床结果表明,RRTIS的风险越大,OM-85的益处越大。 OM-85可以被认为是加入到耳朵,鼻子和喉咙(耳朵)的有限盔甲的有前途的工具,以及他们与RRTIS及其并发症的耳朵和并发症,例如反复喘息和哮喘初始化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号